Pfizer’s Shedlarz To Retire By Year End
This article was originally published in The Pink Sheet Daily
Departure of Shedlarz follows several other high-profile exits since CEO Kindler took the helm last year.
You may also be interested in...
Two Pfizer Veterans To Leave Firm
R&D head LaMattina and CFO Levin have 50 years of experience with Pfizer between them.
Pfizer Restructuring Expands Shedlarz' Responsibilities As Katen Departs
New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.